Get the Stockscreener App
32.18
0.53%
-0.17
After Hours:
32.08
-0.10
-0.31%
Ideaya Biosciences Inc stock is traded at $32.18, with a volume of 2.16M.
It is down -0.53% in the last 24 hours and down -2.75% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$32.35
Open:
$32.57
24h Volume:
2.16M
Relative Volume:
1.91
Market Cap:
$2.83B
Revenue:
$218.71M
Net Income/Loss:
$-113.70M
P/E Ratio:
-24.69
EPS:
-1.3034
Net Cash Flow:
$-73.47M
1W Performance:
+3.94%
1M Performance:
-2.75%
6M Performance:
+13.39%
1Y Performance:
+89.52%
1-Day Range:
$31.00
$32.84
1-Week Range:
$30.18
$38.10
52-Week Range:
$15.84
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
32.18 | 2.84B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Yahoo Finance
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal MelanomaSlideshow (NASDAQ:IDYA) 2026-04-13 - Seeking Alpha
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
Mizuho raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
Ideaya Biosciences: Stock Buoyant On Good mUM DataBut Approval Not A Formality (IDYA) - Seeking Alpha
Truist raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
IDEAYA’s uveal melanoma drug combo meets trial goals By Investing.com - Investing.com Australia
Goldman Sachs raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
Goldman Sachs raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
IDEAYA Biosciences (IDYA) Stock Jumps 26% After Eye Cancer Trial Blows Past Standard Care - MEXC
IDEAYA Biosciences Announces Phase 2/3 Clinical Update for Darovasertib Combination in OptimUM-02 Trial - Minichart
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - Reuters
IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data - MEXC
Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why. - Barron's
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsIDEAYA Biosciences (NASDAQ:IDYA) - Benzinga
IDYA: Darovasertib plus crizotinib doubled PFS and improved ORR in HLA-A*02:01-negative mUM - TradingView — Track All Markets
IDEAYA Biosciences stock surges 27% on trial results - Investing.com
IDEAYA’s uveal melanoma drug combo meets trial goals - Investing.com
IDEAYA Biosciences' darovasertib+crizotinib cuts progression risk 58%, median PFS 6.9 vs 3.1 months - TradingView — Track All Markets
Darovasertib combo boosts PFS in IDEAYA (NASDAQ: IDYA) uveal melanoma trial - Stock Titan
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PR Newswire
Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Dip Buying: Can IDEAYA Biosciences Inc reach all time highs this year2026 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn
Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - BioSpace
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 Op - GuruFocus
IDYA Stock Pops As New Cancer Trials Ignite Trader Focus - timothysykes.com
Ideaya Biosciences to announce topline results from phase 2/3 Optimum-02 trial in metastatic uveal melanoma on Monday, April 13, 2026 - marketscreener.com
Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026 - TradingView — Track All Markets
IDEAYA to report uveal melanoma trial results Monday By Investing.com - Investing.com UK
IDEAYA to reveal April 13 trial data in metastatic uveal melanoma - Stock Titan
(IDYA) Volatility Zones as Tactical Triggers - Stock Traders Daily
IDEAYA’s April 13 PFS Results May Lead to Fast-Track Approval or Significant Revaluation - Bitget
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com
IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial - TipRanks
Ideaya Biosciences Incenters clinical collaboration agreement with AstraZeneca on April 8, 2026SEC filing - marketscreener.com
IDEAYA Biosciences IncAdvancing Global Pha - Moomoo
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha
IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Jefferies Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $52 - Moomoo
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - MarketBeat
Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView — Track All Markets
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):